<DOC>
	<DOCNO>NCT00547521</DOCNO>
	<brief_summary>To evaluate safety immunogenicity abatacept use without methotrexate absence IV load dose abatacept</brief_summary>
	<brief_title>Phase IIIB Subcutaneous Abatacept Monotherapy Study</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Clinical diagnosis Rheumatoid Arthritis Subjects Global Disease Assessment great equal 20 mm visual analog scale Discontinue Biologics Diseasemodifying antirheumatic drug ( DMARDS ) except methotrexate Received treatment rituximab Subjects receive treatment immunoadsorbtion column ( Prosorba column ) , mycophenolate mofetil ( CellceptÂ® ) , cyclosporine A calcineurin inhibitor , DPenicillamine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>